# Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Study · id `cardio:ct-nct03346057` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03346057](<https://clinicaltrials.gov/study/NCT03346057>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03346057

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.

## Technical summary

Registry record NCT03346057. Randomized; triple masking; primary purpose treatment. Start 2017-12-20 (actual); primary completion 2019-09-04 (actual). Results posted on 2020-10-08.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 344 participants (enrolled count; ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Started: 2017-12-20 (actual) (ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Primary completion: 2019-09-04 (actual) (ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Completion: 2019-09-04 (actual) (ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Results first posted: 2020-10-08 (ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Countries: United States; Austria; Denmark; Germany (ClinicalTrials.gov record NCT03346057, source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03346057-2020-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
- Condition: Reversal of Neuromuscular Blockade
- Intervention (Drug): Sugammadex 2 mg/kg
- Intervention (Drug): Sugammadex 4 mg/kg
- Intervention (Drug): Sugammadex 16 mg/kg
- Intervention (Drug): Neostigmine + Glycopyrrolate
- Intervention (Drug): Rocuronium
- Intervention (Drug): Vecuronium
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants (`cardio:pubmed-34711192`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: deb02427309d6f7dd20111fecb5140512aff23e44e8b486a8ae896d02292ec34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
